<?xml version='1.0'?><!DOCTYPE Annotation PUBLIC "//GENIA//DTD GENIA ANNOTATION EVENT 2.0//EN_Modified" "../ModifiedGENIAtypes/Modified_GENIA_event_20.dtd"><Annotation annotates="http://www.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;retmode=xml&amp;rettype=medline&amp;id=9796963" created="07/05/2006" creator="Noriko Katsu"><PubmedArticleSet><PubmedArticle><MedlineCitation>
<PMID>9796963</PMID>
<Article>
<ArticleTitle>
<sentence id="S1"><term id="T1" lex="signal_transduction_abnormality" sem="Other">Signal transduction abnormalities</term> in <term id="T2" lex="T_lymphocyte" sem="Cell_natural">T lymphocytes</term> from <term id="T3" lex="patient" sem="Multicellular_organism_natural">patients</term> with advanced <term id="T4" lex="renal_carcinoma" sem="Other">renal carcinoma</term>: clinical relevance and effects of <term id="T5" lex="cytokine_therapy" sem="Other"><term id="T6" lex="cytokine" sem="Protein_family_or_group">cytokine</term> therapy</term>.</sentence>
<event KT="Investigation" id="E72">
<type class="Regulation"/>
<theme idref="T1"/>
<cause idref="T6"/>
<clue>Signal transduction abnormalities <clueLoc>in T lymphocytes from patients with advanced renal carcinoma</clueLoc>: clinical relevance and <clueType>effects</clueType> <linkCause>of</linkCause> cytokine therapy.</clue>
</event>
</ArticleTitle>
<Abstract>
<AbstractText>
<sentence id="S2">Studies have demonstrated abnormalities of the <term id="T7" lex="CD3/T-cell_antigen_receptor" sem="Protein_molecule"><term id="A7" sem="Peptide">CD3</term>/T-cell antigen receptor</term> (<term id="T8" lex="TCR" sem="Protein_molecule">TCR</term>) and pathways of <term id="T9" lex="signal_transduction" sem="Other">signal transduction</term> in <term id="T10" lex="T_lymphocyte" sem="Cell_natural">T lymphocytes</term> from animals and <term id="T11" lex="patient" sem="Multicellular_organism_natural">patients</term> with <term id="T12" lex="advanced_malignancy" sem="Other">advanced malignancy</term>.</sentence>
<sentence id="S3">Diminished expression of <term id="T13" lex="TCRzeta" sem="Protein_molecule">TCRzeta</term> and <term id="T14" lex="p56(lck)" sem="Protein_molecule">p56(lck)</term> that are associated with the <term id="T15" lex="TCR" sem="Protein_molecule">TCR</term> and reduced nuclear localization of <term id="T16" lex="RelA_containing_nuclear_factor_kappaB_(NFkappaB)_complex" sem="Protein_complex"><term id="T17" lex="RelA" sem="Protein_molecule">RelA</term> containing nuclear factor kappaB (<term id="T18" lex="NFkappaB" sem="Protein_complex">NFkappaB</term>) complexes</term> have been noted.</sentence>
<event KT="Other" id="E4">
<type class="Gene_expression"/>
<theme idref="T13"/>
<clue>Diminished <clueType>expression</clueType> <linkTheme>of</linkTheme> TCRzeta and p56(lck) that are associated with the TCR and reduced nuclear localization of RelA containing nuclear factor kappaB (NFkappaB) complexes have been noted.</clue>
</event>
<event KT="Other" id="E5">
<type class="Gene_expression"/>
<theme idref="T14"/>
<clue>Diminished <clueType>expression</clueType> <linkTheme>of</linkTheme> TCRzeta and p56(lck) that are associated with the TCR and reduced nuclear localization of RelA containing nuclear factor kappaB (NFkappaB) complexes have been noted.</clue>
</event>
<event KT="Analysis" id="E6">
<type class="Binding"/>
<theme idref="T13"/>
<theme idref="T15"/>
<clue>Diminished expression of TCRzeta and p56(lck) that are <clueType><clueKT>associated</clueKT></clueType> <linkTheme>with</linkTheme> the TCR and reduced nuclear localization of RelA containing nuclear factor kappaB (NFkappaB) complexes have been noted.</clue>
</event>
<event KT="Analysis" id="E7">
<type class="Binding"/>
<theme idref="T14"/>
<theme idref="T15"/>
<clue>Diminished expression of TCRzeta and p56(lck) that are <clueType><clueKT>associated</clueKT></clueType> <linkTheme>with</linkTheme> the TCR and reduced nuclear localization of RelA containing nuclear factor kappaB (NFkappaB) complexes have been noted.</clue>
</event>
<event KT="Analysis" id="E8">
<type class="Negative_regulation"/>
<theme idref="E4"/>
<clue><clueType>Diminished</clueType> expression of TCRzeta and p56(lck) that are associated with the TCR and reduced nuclear localization of RelA containing nuclear factor kappaB (NFkappaB) complexes have been <clueKT>noted</clueKT>.</clue>
</event>
<event KT="Analysis" id="E9">
<type class="Negative_regulation"/>
<theme idref="E5"/>
<clue><clueType>Diminished</clueType> expression of TCRzeta and p56(lck) that are associated with the TCR and reduced nuclear localization of RelA containing nuclear factor kappaB (NFkappaB) complexes have been <clueKT>noted</clueKT>.</clue>
</event>
<event KT="Other" id="E10">
<type class="Localization"/>
<theme idref="T16"/>
<clue>Diminished expression of TCRzeta and p56(lck) that are associated with the TCR and reduced <clueLoc>nuclear</clueLoc> <clueType>localization</clueType> <linkTheme>of</linkTheme> RelA containing nuclear factor kappaB (NFkappaB) complexes have been noted.</clue>
</event>
<event KT="Other" id="E71">
<type class="Negative_regulation"/>
<theme idref="E10"/>
<clue>Diminished expression of TCRzeta and p56(lck) that are associated with the TCR and <clueType>reduced</clueType> nuclear localization of RelA containing nuclear factor kappaB (NFkappaB) complexes have been noted.</clue>
</event>
<sentence id="S4">These defects have been described in <term id="T19" lex="T_cell" sem="Cell_natural">T cells</term> from <term id="T20" lex="patient" sem="Multicellular_organism_natural">patients</term> with <term id="T21" lex="malignant_melanoma" sem="Other">malignant melanoma</term>, <term id="T22" lex="renal_cell_carcinoma" sem="Other">renal cell carcinoma</term> (<term id="T23" lex="RCC" sem="Other">RCC</term>), <term id="T24" lex="ovarian_cancer" sem="Other">ovarian cancer</term>, and <term id="T25" lex="colorectal_cancer" sem="Other">colorectal cancer</term>.</sentence>
<event KT="Analysis" Source="Other" id="E11">
<type class="Negative_regulation"/>
<theme idref="E8"/>
<clue><corefTheme>These</corefTheme> <clueType>defects</clueType> <clueSource>have been</clueSource> <clueKT>described</clueKT> <clueLoc>in T cells</clueLoc> from patients with malignant melanoma, renal cell carcinoma (RCC), ovarian cancer, and colorectal cancer.</clue>
</event>
<event KT="Analysis" Source="Other" id="E12">
<type class="Negative_regulation"/>
<theme idref="E9"/>
<clue><corefTheme>These</corefTheme> <clueType>defects</clueType> <clueSource>have been</clueSource> <clueKT>described</clueKT> <clueLoc>in T cells</clueLoc> from patients with malignant melanoma, renal cell carcinoma (RCC), ovarian cancer, and colorectal cancer.</clue>
</event>
<event KT="Analysis" Source="Other" id="E73">
<type class="Negative_regulation"/>
<theme idref="E71"/>
<clue><corefTheme>These</corefTheme> <clueType>defects</clueType> <clueSource>have been</clueSource> <clueKT>described</clueKT> <clueLoc>in T cells</clueLoc> from patients with malignant melanoma, renal cell carcinoma (RCC), ovarian cancer, and colorectal cancer.</clue>
</event>
<sentence id="S5">Preliminary observations also indicate possible correlation with clinical variables such as stage in selected instances.</sentence>
<sentence id="S6">To further characterize altered expression of <term id="T26" lex="TCRzeta" sem="Protein_molecule">TCRzeta</term>, <term id="T27" lex="p56(lck)" sem="Protein_molecule">p56(lck)</term>, and impaired activation of <term id="T28" lex="NFkappaB" sem="Protein_complex">NFkappaB</term>, <term id="T29" lex="T_lymphocyte" sem="Cell_natural">T lymphocytes</term> were obtained from 65 <term id="T30" lex="patient" sem="Multicellular_organism_natural">patients</term> with <term id="T31" lex="RCC" sem="Other">RCC</term>, the majority of whom were receiving combination <term id="T32" lex="cytokine_therapy" sem="Other"><term id="T33" lex="cytokine" sem="Protein_family_or_group">cytokine</term> therapy</term> [<term id="T34" lex="interleukin_(IL)-2" sem="Protein_molecule">interleukin (IL)-2</term>, <term id="T35" lex="IFN_alpha-containing_regimen" sem="Other"><term id="T36" lex="IFN_alpha" sem="Protein_molecule">IFN alpha</term>-containing regimens</term>] and 37 control individuals.</sentence>
<event KT="Investigation" id="E13" uncertainty="doubtful">
<type class="Negative_regulation"/>
<theme idref="E15"/>
<clue><clueKT>To</clueKT> further <clueKT>characterize</clueKT> <clueType>altered</clueType> expression of TCRzeta, p56(lck), and impaired activation of NFkappaB, <clueLoc>T lymphocytes</clueLoc> were obtained from 65 patients with RCC, the majority of whom were receiving combination cytokine therapy [interleukin (IL)-2, IFN alpha-containing regimens] and 37 control individuals.</clue>
<comment>CAUTION: altered = diminished</comment></event>
<event KT="Investigation" id="E14" uncertainty="doubtful">
<type class="Negative_regulation"/>
<theme idref="E16"/>
<clue><clueKT>To</clueKT> further <clueKT>characterize</clueKT> <clueType>altered</clueType> expression of TCRzeta, p56(lck), and impaired activation of NFkappaB, <clueLoc>T lymphocytes</clueLoc> were obtained from 65 patients with RCC, the majority of whom were receiving combination cytokine therapy [interleukin (IL)-2, IFN alpha-containing regimens] and 37 control individuals.</clue>
<comment>CAUTION: altered = diminished</comment></event>
<event KT="Other" id="E15">
<type class="Gene_expression"/>
<theme idref="T26"/>
<clue>To further characterize altered <clueType>expression</clueType> <linkTheme>of</linkTheme> TCRzeta, p56(lck), and impaired activation of NFkappaB, T lymphocytes were obtained from 65 patients with RCC, the majority of whom were receiving combination cytokine therapy [interleukin (IL)-2, IFN alpha-containing regimens] and 37 control individuals.</clue>
</event>
<event KT="Other" id="E16">
<type class="Gene_expression"/>
<theme idref="T27"/>
<clue>To further characterize altered <clueType>expression</clueType> <linkTheme>of</linkTheme> TCRzeta, p56(lck), and impaired activation of NFkappaB, T lymphocytes were obtained from 65 patients with RCC, the majority of whom were receiving combination cytokine therapy [interleukin (IL)-2, IFN alpha-containing regimens] and 37 control individuals.</clue>
</event>
<event KT="Investigation" id="E17" uncertainty="doubtful">
<type class="Negative_regulation"/>
<theme idref="E18"/>
<clue><clueKT>To</clueKT> further <clueKT>characterize</clueKT> altered expression of TCRzeta, p56(lck), and <clueType>impaired</clueType> activation of NFkappaB, <clueLoc>T lymphocytes</clueLoc> were obtained from 65 patients with RCC, the majority of whom were receiving combination cytokine therapy [interleukin (IL)-2, IFN alpha-containing regimens] and 37 control individuals.</clue>
</event>
<event KT="Other" id="E18">
<type class="Positive_regulation"/>
<theme idref="T28"/>
<clue>To further characterize altered expression of TCRzeta, p56(lck), and impaired <clueType>activation</clueType> <linkTheme>of</linkTheme> NFkappaB, T lymphocytes were obtained from 65 patients with RCC, the majority of whom were receiving combination cytokine therapy [interleukin (IL)-2, IFN alpha-containing regimens] and 37 control individuals.</clue>
</event>
<sentence id="S7">In 29 of these <term id="T37" lex="patient" sem="Multicellular_organism_natural">patients</term>, levels of <term id="T38" lex="TCRzeta" sem="Protein_molecule">TCRzeta</term> and <term id="T39" lex="p56(lck)" sem="Protein_molecule">p56(lck)</term> were determined by <term id="T40" lex="Western_blot" sem="Other">Western blots</term> of <term id="T41" lex="T-cell_lysate" sem="Organic_compound_other">T-cell lysates</term> and semiquantitated using <term id="T42" lex="densitometry" sem="Other">densitometry</term>.</sentence>
<event KT="Analysis" id="E19" uncertainty="doubtful">
<type class="Gene_expression"/>
<theme idref="T38"/>
<clue>In 29 of these patients, <clueType>levels</clueType> <linkTheme>of</linkTheme> TCRzeta and p56(lck) were <clueKT>determined</clueKT> <clueExperiment>by Western blots of T-cell lysates and semiquantitated using densitometry</clueExperiment>.</clue>
</event>
<event KT="Analysis" id="E20" uncertainty="doubtful">
<type class="Gene_expression"/>
<theme idref="T39"/>
<clue>In 29 of these patients, <clueType>levels</clueType> <linkTheme>of</linkTheme> TCRzeta and p56(lck) were <clueKT>determined</clueKT> <clueExperiment>by Western blots of T-cell lysates and semiquantitated using densitometry</clueExperiment>.</clue>
</event>
<sentence id="S8">Relative levels were then correlated with a series of <term id="A3" sem="Other">clinical variables</term> including <term id="T43" lex="response_to_therapy" sem="Other">response to therapy</term>, <term id="T44" lex="performance_status" sem="Other">performance status</term>, survival, <term id="T45" lex="disease_site" sem="Other">disease sites</term>, age, and others.</sentence>
<event KT="Analysis" id="E21" uncertainty="doubtful">
<type class="Correlation"/>
<theme idref="E19"/>
<theme idref="A3"/>
<clue><corefTheme>Relative levels</corefTheme> were then <clueType><clueKT>correlated</clueKT></clueType> <linkTheme>with</linkTheme> a series of clinical variables including response to therapy, performance status, survival, disease sites, age, and others.</clue>
</event>
<event KT="Analysis" id="E22" uncertainty="doubtful">
<type class="Correlation"/>
<theme idref="E20"/>
<theme idref="A3"/>
<clue><corefTheme>Relative levels</corefTheme> were then <clueType><clueKT>correlated</clueKT></clueType> <linkTheme>with</linkTheme> a series of clinical variables including response to therapy, performance status, survival, disease sites, age, and others.</clue>
</event>
<sentence id="S9">In another group of 28 <term id="T46" lex="patient" sem="Multicellular_organism_natural">patients</term> (three individuals from the first group), the frequency of <term id="T47" lex="abnormal_NFkappaB_activation" sem="Other">abnormal <term id="T48" lex="NFkappaB" sem="Protein_complex">NFkappaB</term> activation</term> was studied using electrophoretic mobility shift assays after activation of <term id="T49" lex="T_cell" sem="Cell_natural">T cells</term> with <term id="T50" lex="phorbol_myristate_acetate/ionomycin" sem="Organic_compound_other">phorbol myristate acetate/ionomycin</term> or <term id="T51" lex="anti-CD3_monoclonal_antibody" sem="Protein_family_or_group">anti-CD3 monoclonal antibody</term>.</sentence>
<event KT="Other" id="E23" uncertainty="doubtful">
<type class="Positive_regulation"/>
<theme idref="T48"/>
<clue>In another group of 28 patients (three individuals from the first group), the frequency of abnormal NFkappaB <clueType>activation</clueType> was studied using electrophoretic mobility shift assays after activation of T cells with phorbol myristate acetate/ionomycin or anti-CD3 monoclonal antibody.</clue>
<comment>NER: T47 mod</comment></event>
<event KT="Investigation" id="E24" uncertainty="doubtful">
<type class="Negative_regulation"/>
<theme idref="E23"/>
<cause idref="E26"/>
<clue>In another group of 28 patients (three individuals from the first group), the frequency of <clueType>abnormal</clueType> NFkappaB activation was <clueKT>studied</clueKT> using <clueExperiment>electrophoretic mobility shift assays</clueExperiment> <linkCause>after</linkCause> activation of T cells with phorbol myristate acetate/ionomycin or anti-CD3 monoclonal antibody.</clue>
</event>
<event KT="Investigation" id="E25" uncertainty="doubtful">
<type class="Negative_regulation"/>
<theme idref="E23"/>
<cause idref="E27"/>
<clue>In another group of 28 patients (three individuals from the first group), the frequency of <clueType>abnormal</clueType> NFkappaB activation was <clueKT>studied</clueKT> using <clueExperiment>electrophoretic mobility shift assays</clueExperiment> <linkCause>after</linkCause> activation of T cells with phorbol myristate acetate/ionomycin or anti-CD3 monoclonal antibody.</clue>
</event>
<event KT="Other" id="E26">
<type class="Physiological_process"/>
<theme idref="T49"/>
<cause idref="T50"/>
<clue>In another group of 28 patients (three individuals from the first group), the frequency of abnormal NFkappaB activation was studied using electrophoretic mobility shift assays after <clueType>activation</clueType> <linkTheme>of</linkTheme> T cells <linkCause>with</linkCause> phorbol myristate acetate/ionomycin or anti-CD3 monoclonal antibody.</clue>
</event>
<event KT="Other" id="E27">
<type class="Physiological_process"/>
<theme idref="T49"/>
<cause idref="T51"/>
<clue>In another group of 28 patients (three individuals from the first group), the frequency of abnormal NFkappaB activation was studied using electrophoretic mobility shift assays after <clueType>activation</clueType> <linkTheme>of</linkTheme> T cells <linkCause>with</linkCause> phorbol myristate acetate/ionomycin or anti-CD3 monoclonal antibody.</clue>
</event>
<sentence id="S10">Changes in these signaling molecules during <term id="T52" lex="cytokine_treatment" sem="Other"><term id="T53" lex="cytokine" sem="Protein_family_or_group">cytokine</term> treatment</term> were also investigated.</sentence>
<event KT="Investigation" id="E28" uncertainty="doubtful">
<type class="Positive_regulation"/>
<theme idref="T38"/>
<cause idref="T52"/>
<clue><clueType>Changes</clueType> <linkTheme>in</linkTheme> <corefTheme>these signaling molecules</corefTheme> <linkCause>during</linkCause> cytokine treatment were also <clueKT>investigated</clueKT>.</clue>
</event>
<event KT="Investigation" id="E29" uncertainty="doubtful">
<type class="Positive_regulation"/>
<theme idref="T39"/>
<cause idref="T52"/>
<clue><clueType>Changes</clueType> <linkTheme>in</linkTheme> <corefTheme>these signaling molecules</corefTheme> <linkCause>during</linkCause> cytokine treatment were also <clueKT>investigated</clueKT>.</clue>
</event>
<sentence id="S11"><term id="T54" lex="TCRzeta" sem="Protein_molecule">TCRzeta</term> and <term id="T55" lex="p56(lck)" sem="Protein_molecule">p56(lck)</term> were detected in the <term id="T56" lex="peripheral_blood_T_cell" sem="Cell_natural">peripheral blood T cells</term> in 27 of 29 <term id="T57" lex="patient" sem="Multicellular_organism_natural">patients</term>, and overall, reduced levels were noted visually in 12 of 29 (41%) and 13 of 29 (45%) individuals, respectively.</sentence>
<event KT="Analysis" id="E30">
<type class="Gene_expression"/>
<theme idref="T54"/>
<clue>TCRzeta and p56(lck) were <clueType><clueKT>detected</clueKT></clueType> <clueLoc>in the peripheral blood T cells</clueLoc> in 27 of 29 patients, and overall, reduced levels were noted visually in 12 of 29 (41%) and 13 of 29 (45%) individuals, respectively.</clue>
</event>
<event KT="Analysis" id="E31">
<type class="Gene_expression"/>
<theme idref="T55"/>
<clue>TCRzeta and p56(lck) were <clueType><clueKT>detected</clueKT></clueType> <clueLoc>in the peripheral blood T cells</clueLoc> in 27 of 29 patients, and overall, reduced levels were noted visually in 12 of 29 (41%) and 13 of 29 (45%) individuals, respectively.</clue>
</event>
<event id="E32">
<type class="Negative_regulation"/>
<theme idref="E30"/>
<clue>TCRzeta and p56(lck) were detected in the peripheral blood T cells in 27 of 29 patients, and overall, <clueType>reduced</clueType> levels were <clueKT>noted</clueKT> visually in 12 of 29 (41%) and 13 of 29 (45%) individuals, respectively.</clue>
</event>
<event id="E33">
<type class="Negative_regulation"/>
<theme idref="E30"/>
<clue>TCRzeta and p56(lck) were detected in the peripheral blood T cells in 27 of 29 patients, and overall, <clueType>reduced</clueType> levels were <clueKT>noted</clueKT> visually in 12 of 29 (41%) and 13 of 29 (45%) individuals, respectively.</clue>
</event>
<sentence id="S12">When levels were semiquantitated using <term id="T58" lex="densitometry" sem="Other">densitometry</term>, significant decreases of <term id="T59" lex="TCRzeta" sem="Protein_molecule">TCRzeta</term> (P = 0.029) and <term id="T60" lex="p56(lck)" sem="Protein_molecule">p56(lck)</term> (P = 0.029) but not <term id="T61" lex="CD3epsilon" sem="Protein_molecule">CD3epsilon</term> (P = 0.131), compared with control levels, were found.</sentence>
<event Manner="High" id="E35">
<type class="Negative_regulation"/>
<theme idref="T59"/>
<clue>When levels were <clueExperiment>semiquantitated using densitometry</clueExperiment>, <clueManner>significant</clueManner> <clueType>decreases</clueType> <linkTheme>of</linkTheme> TCRzeta (P = 0.029) and p56(lck) (P = 0.029) but not CD3epsilon (P = 0.131), compared with control levels, were <clueKT>found</clueKT>.</clue>
</event>
<event Manner="High" id="E36">
<type class="Negative_regulation"/>
<theme idref="T60"/>
<clue>When levels were <clueExperiment>semiquantitated using densitometry</clueExperiment>, <clueManner>significant</clueManner> <clueType>decreases</clueType> <linkTheme>of</linkTheme> TCRzeta (P = 0.029) and p56(lck) (P = 0.029) but not CD3epsilon (P = 0.131), compared with control levels, were <clueKT>found</clueKT>.</clue>
</event>
<event Manner="High" Polarity="Negative" assertion="non-exist" id="E37">
<type class="Negative_regulation"/>
<theme idref="T61"/>
<clue>When levels were <clueExperiment>semiquantitated using densitometry</clueExperiment>, <clueManner>significant</clueManner> <clueType>decreases</clueType> <linkTheme>of</linkTheme> TCRzeta (P = 0.029) and p56(lck) (P = 0.029) but <cluePolarity>not</cluePolarity> CD3epsilon (P = 0.131), compared with control levels, were <clueKT>found</clueKT>.</clue>
</event>
<sentence id="S13">In <term id="T62" lex="patient" sem="Multicellular_organism_natural">patients</term> treated with <term id="A5" sem="Protein_molecule">IL-2</term>/<term id="T63" lex="IFN_alpha-based_therapy" sem="Other"><term id="T64" lex="IFN_alpha" sem="Protein_molecule">IFN alpha</term>-based therapy</term>, relative levels of <term id="T65" lex="TCRzeta" sem="Protein_molecule">TCRzeta</term> increased significantly (P = 0.002) on day 15 of cycle one compared with the baseline.</sentence>
<event Manner="High" id="E38">
<type class="Positive_regulation"/>
<theme idref="T65"/>
<cause idref="A5"/>
<cause idref="T64"/>
<clue>In patients treated <linkCause>with</linkCause> IL-2/IFN alpha-based therapy, relative levels of TCRzeta <clueType>increased</clueType> <clueManner>significantly</clueManner> (P = 0.002) <clueTime>on day 15 of cycle one</clueTime> compared with the baseline.</clue>
</event>
<sentence id="S14">Correlations of <term id="T66" lex="TCRzeta" sem="Protein_molecule">TCRzeta</term> or <term id="T67" lex="p56(lck)" sem="Protein_molecule">p56(lck)</term> levels with response or disease variables, except for lower <term id="T68" lex="TCRzeta_level" sem="Other"><term id="T69" lex="TCRzeta" sem="Protein_molecule">TCRzeta</term> levels</term> (P &lt; 0.001) in the presence of <term id="T70" lex="bone_metastasis" sem="Tissue_natural">bone metastases</term>, were not found.</sentence>
<event id="E39">
<type class="Negative_regulation"/>
<theme idref="T69"/>
<cause idref="T70"/>
<clue>Correlations of TCRzeta or p56(lck) levels with response or disease variables, except for <clueType>lower</clueType> TCRzeta <clueType>levels</clueType> (P &lt; 0.001) <linkCause>in the presence of</linkCause> bone metastases, were not <clueKT>found</clueKT>.</clue>
</event>
<sentence id="S15"><term id="T71" lex="abnormal_NFkappaB_activation" sem="Other">Abnormal <term id="T72" lex="NFkappaB" sem="Protein_complex">NFkappaB</term> activation</term> after stimulation with <term id="T73" lex="phorbol_myristate_acetate/ionomycin" sem="Organic_compound_other">phorbol myristate acetate/ionomycin</term> and/or <term id="T74" lex="anti-CD3_monoclonal_antibody" sem="Protein_family_or_group">anti-CD3 monoclonal antibody</term> was found in 59% of <term id="T75" lex="patient" sem="Multicellular_organism_natural">patients</term> (17 of 28) and was not accounted for by the advanced age of the study cohort.</sentence>
<event KT="Other" id="E40">
<type class="Positive_regulation"/>
<theme idref="T72"/>
<cause idref="E43"/>
<clue>Abnormal NFkappaB <clueType>activation</clueType> <linkCause>after</linkCause> stimulation with phorbol myristate acetate/ionomycin and/or anti-CD3 monoclonal antibody was found in 59% of patients (17 of 28) and was not accounted for by the advanced age of the study cohort.</clue>
</event>
<event KT="Other" id="E1">
<type class="Positive_regulation"/>
<theme idref="T72"/>
<cause idref="E44"/>
<clue>Abnormal NFkappaB <clueType>activation</clueType> <linkCause>after</linkCause> stimulation with phorbol myristate acetate/ionomycin and/or anti-CD3 monoclonal antibody was found in 59% of patients (17 of 28) and was not accounted for by the advanced age of the study cohort.</clue>
</event>
<event KT="Analysis" id="E41">
<type class="Negative_regulation"/>
<theme idref="E40"/>
<clue><clueType><clueKT>Abnormal</clueKT></clueType> NFkappaB activation after stimulation with phorbol myristate acetate/ionomycin and/or anti-CD3 monoclonal antibody was found in 59% of patients (17 of 28) and was not accounted for by the advanced age of the study cohort.</clue>
<comment>CAUTION, abnormal</comment></event>
<event KT="Analysis" id="E42">
<type class="Negative_regulation"/>
<theme idref="E1"/>
<cause idref="E43"/>
<clue><clueType><clueKT>Abnormal</clueKT></clueType> NFkappaB activation after stimulation with phorbol myristate acetate/ionomycin and/or anti-CD3 monoclonal antibody was found in 59% of patients (17 of 28) and was not accounted for by the advanced age of the study cohort.</clue>
<comment>CAUTION, abnormal</comment></event>
<event KT="Other" id="E43">
<type class="Positive_regulation"/>
<cause idref="T73"/>
<clue>Abnormal NFkappaB activation after <clueType>stimulation</clueType> <linkCause>with</linkCause> phorbol myristate acetate/ionomycin and/or anti-CD3 monoclonal antibody was found in 59% of patients (17 of 28) and was not accounted for by the advanced age of the study cohort.</clue>
<comment>NO THEME</comment></event>
<event KT="Other" id="E44">
<type class="Positive_regulation"/>
<cause idref="T74"/>
<clue>Abnormal NFkappaB activation after <clueType>stimulation</clueType> <linkCause>with</linkCause> phorbol myristate acetate/ionomycin and/or anti-CD3 monoclonal antibody was found in 59% of patients (17 of 28) and was not accounted for by the advanced age of the study cohort.</clue>
<comment>NO THEME</comment></event>
<sentence id="S16">Activation of <term id="T76" lex="NFkappaB" sem="Protein_complex">NFkappaB</term> in <term id="T77" lex="peripheral_blood_T_cell" sem="Cell_natural">peripheral blood T cells</term> was inducible during <term id="T78" lex="cytokine_therapy" sem="Other"><term id="T79" lex="cytokine" sem="Protein_family_or_group">cytokine</term> therapy</term> in four of six individuals who displayed impaired <term id="T80" lex="NFkappaB" sem="Protein_complex">NFkappaB</term> activity prior to therapy.</sentence>
<event id="E45">
<type class="Positive_regulation"/>
<theme idref="T76"/>
<clue><clueType>Activation</clueType> <linkTheme>of</linkTheme> NFkappaB <clueLoc>in peripheral blood T cells</clueLoc> was inducible during cytokine therapy in four of six individuals who displayed impaired NFkappaB activity prior to therapy.</clue>
</event>
<event id="E46">
<type class="Positive_regulation"/>
<theme idref="E45"/>
<cause idref="T78"/>
<clue>Activation of NFkappaB in peripheral blood T cells was <clueType>inducible</clueType> <linkCause>during</linkCause> cytokine therapy in four of six individuals who displayed impaired NFkappaB activity prior to therapy.</clue>
</event>
<sentence id="S17">Moreover, impaired activation of <term id="T81" lex="NFkappaB" sem="Protein_complex">NFkappaB</term> does not appear linked to a reduction of <term id="T82" lex="TCRzeta_expression" sem="Other"><term id="T83" lex="TCRzeta" sem="Protein_molecule">TCRzeta</term> expression</term>, because in five <term id="T84" lex="patient" sem="Multicellular_organism_natural">patients</term>, <term id="T85" lex="normal_TCRzeta_level" sem="Other">normal <term id="T86" lex="TCRzeta" sem="Protein_molecule">TCRzeta</term> levels</term> were present although <term id="T87" lex="kappaB" sem="Protein_molecule">kappaB</term> binding was not inducible.</sentence>
<event KT="Other" id="E47">
<type class="Positive_regulation"/>
<theme idref="T81"/>
<clue>Moreover, impaired <clueType>activation</clueType> <linkTheme>of</linkTheme> NFkappaB does not appear linked to a reduction of TCRzeta expression, because in five patients, normal TCRzeta levels were present although kappaB binding was not inducible.</clue>
</event>
<event KT="Other" id="E48">
<type class="Negative_regulation"/>
<theme idref="E47"/>
<clue>Moreover, <clueType>impaired</clueType> activation of NFkappaB does not appear linked to a reduction of TCRzeta expression, because in five patients, normal TCRzeta levels were present although kappaB binding was not inducible.</clue>
</event>
<event CL="L2" KT="Analysis" Polarity="Negative" assertion="non-exist" id="E49" uncertainty="probable">
<type class="Correlation"/>
<theme idref="E48"/>
<theme idref="E51"/>
<clue>Moreover, impaired activation of NFkappaB does <cluePolarity>not</cluePolarity> <clueCL>appear</clueCL> <clueType><clueKT>linked</clueKT></clueType> to a reduction of TCRzeta expression, because in five patients, normal TCRzeta levels were present although kappaB binding was not inducible.</clue>
</event>
<event KT="Other" id="E50">
<type class="Gene_expression"/>
<theme idref="T83"/>
<clue>Moreover, impaired activation of NFkappaB does not appear linked to a reduction of TCRzeta <clueType>expression</clueType>, because in five patients, normal TCRzeta levels were present although kappaB binding was not inducible.</clue>
</event>
<event KT="Other" id="E51">
<type class="Negative_regulation"/>
<theme idref="E50"/>
<clue>Moreover, impaired activation of NFkappaB does not appear linked to a <clueType>reduction</clueType> <linkTheme>of</linkTheme> TCRzeta expression, because in five patients, normal TCRzeta levels were present although kappaB binding was not inducible.</clue>
</event>
<event KT="Other" id="E52">
<type class="Binding"/>
<theme idref="T87"/>
<clue>Moreover, impaired activation of NFkappaB does not appear linked to a reduction of TCRzeta expression, because in five patients, normal TCRzeta levels were present although kappaB <clueType>binding</clueType> was not inducible.</clue>
</event>
<event Polarity="Negative" assertion="non-exist" id="E53" uncertainty="probable">
<type class="Positive_regulation"/>
<theme idref="E52"/>
<clue>Moreover, impaired activation of NFkappaB does not appear linked to a reduction of TCRzeta expression, because in five patients, normal TCRzeta levels were present although kappaB binding was <cluePolarity>not</cluePolarity> <clueType>inducible</clueType>.</clue>
</event>
<event KT="Analysis" Polarity="Negative" assertion="non-exist" id="E54">
<type class="Correlation"/>
<theme idref="T85"/>
<theme idref="E53"/>
<clue>Moreover, impaired activation of NFkappaB does not appear linked to a reduction of TCRzeta expression, because in five patients, <clueKT>normal</clueKT> TCRzeta levels were <clueType>present</clueType> <linkTheme><cluePolarity>although</cluePolarity></linkTheme> kappaB binding was not inducible.</clue>
</event>
<sentence id="S18">In the majority of <term id="T88" lex="patient" sem="Multicellular_organism_natural">patients</term> with advanced <term id="T89" lex="RCC" sem="Other">RCC</term>, <term id="T90" lex="peripheral_blood_T_cell" sem="Cell_natural">peripheral blood T cells</term> express <term id="T91" lex="TCRzeta" sem="Protein_molecule">TCRzeta</term> and <term id="T92" lex="p56(lck)" sem="Protein_molecule">p56(lck)</term>, and in a subset, reduced levels of these <term id="T93" lex="TCRzeta_associated_molecule" sem="Protein_family_or_group"><term id="T94" lex="TCRzeta" sem="Protein_molecule">TCRzeta</term> associated molecules</term> are seen that may increase during <term id="T95" lex="cytokine-based_therapy" sem="Other"><term id="T96" lex="cytokine" sem="Protein_family_or_group">cytokine</term>-based therapy</term>.</sentence>
<event id="E55">
<type class="Gene_expression"/>
<theme idref="T91"/>
<clue>In the majority of patients with advanced RCC, <clueLoc>peripheral blood T cells</clueLoc> <clueType>express</clueType> TCRzeta and p56(lck), and in a subset, reduced levels of these TCRzeta associated molecules are seen that may increase during cytokine-based therapy.</clue>
</event>
<event id="E56">
<type class="Gene_expression"/>
<theme idref="T92"/>
<clue>In the majority of patients with advanced RCC, <clueLoc>peripheral blood T cells</clueLoc> <clueType>express</clueType> TCRzeta and p56(lck), and in a subset, reduced levels of these TCRzeta associated molecules are seen that may increase during cytokine-based therapy.</clue>
</event>
<event id="E57">
<type class="Negative_regulation"/>
<theme idref="T91"/>
<clue>In the majority of patients with advanced RCC, peripheral blood T cells express TCRzeta and p56(lck), and <clueLoc>in a subset</clueLoc>, <clueType>reduced levels</clueType> <linkTheme>of</linkTheme> <corefTheme>these TCRzeta associated molecules</corefTheme> are <clueKT>seen</clueKT> that may increase during cytokine-based therapy.</clue>
</event>
<event id="E58">
<type class="Negative_regulation"/>
<theme idref="T92"/>
<clue>In the majority of patients with advanced RCC, peripheral blood T cells express TCRzeta and p56(lck), and <clueLoc>in a subset</clueLoc>, <clueType>reduced levels</clueType> <linkTheme>of</linkTheme> <corefTheme>these TCRzeta associated molecules</corefTheme> are <clueKT>seen</clueKT> that may increase during cytokine-based therapy.</clue>
</event>
<event CL="L1" KT="Analysis" id="E59">
<type class="Positive_regulation"/>
<theme idref="E57"/>
<cause idref="T95"/>
<clue>In the majority of patients with advanced RCC, peripheral blood T cells express TCRzeta and p56(lck), and in a subset, reduced levels of these TCRzeta associated molecules are seen that <clueKT><clueCL>may</clueCL></clueKT> <clueType>increase</clueType> <linkCause>during</linkCause> cytokine-based therapy.</clue>
</event>
<event CL="L1" KT="Analysis" id="E60">
<type class="Positive_regulation"/>
<theme idref="E58"/>
<cause idref="T95"/>
<clue>In the majority of patients with advanced RCC, peripheral blood T cells express TCRzeta and p56(lck), and in a subset, reduced levels of these TCRzeta associated molecules are seen that <clueKT><clueCL>may</clueCL></clueKT> <clueType>increase</clueType> <linkCause>during</linkCause> cytokine-based therapy.</clue>
</event>
<sentence id="S19">Abnormal activation of <term id="T97" lex="NFkappaB" sem="Protein_complex">NFkappaB</term> is also present in &gt;50% of <term id="T98" lex="patient" sem="Multicellular_organism_natural">patients</term> and may also revert to normal during <cons id="C1" lex="(/ IL-2-based_treatment IFN_alpha-based_treatment)" sem="(/ Other Other)"><frag id="F1"><term id="A6" sem="Protein_molecule">IL-2</term></frag>/<frag id="F2"><term id="T100" lex="IFN_alpha" sem="Protein_molecule">IFN alpha</term></frag><frag id="F3">-based treatment</frag></cons>.</sentence>
<event KT="Other" id="E61">
<type class="Positive_regulation"/>
<theme idref="T97"/>
<clue>Abnormal <clueType>activation</clueType> <linkTheme>of</linkTheme> NFkappaB is also present in &gt;50% of patients and may also revert to normal during IL-2/IFN alpha-based treatment.</clue>
</event>
<event KT="Analysis" id="E62">
<type class="Negative_regulation"/>
<theme idref="E61"/>
<clue><clueType><clueKT>Abnormal</clueKT></clueType> activation of NFkappaB is also present in &gt;50% of patients and may also revert to normal during IL-2/IFN alpha-based treatment.</clue>
<comment>CAUTION, abnormal</comment></event>
<event CL="L1" KT="Analysis" id="E63">
<type class="Negative_regulation"/>
<theme idref="E62"/>
<cause idref="A6"/>
<cause idref="T100"/>
<clue>Abnormal activation of NFkappaB is also present in &gt;50% of patients and <clueKT><clueCL>may</clueCL></clueKT> also <clueType>revert to normal</clueType> <linkCause>during</linkCause> IL-2/IFN alpha-based treatment.</clue>
</event>
<sentence id="S20">This alteration in <term id="T101" lex="NFkappaB_activation" sem="Other"><term id="T102" lex="NFkappaB" sem="Protein_complex">NFkappaB</term> activation</term> occurred in the presence of normal expression of <term id="T103" lex="TCRzeta-associated_signaling_element" sem="DNA_family_or_group"><term id="T104" lex="TCRzeta" sem="Protein_molecule">TCRzeta</term>-associated signaling elements</term>.</sentence>
<event id="E64">
<type class="Positive_regulation"/>
<theme idref="E65"/>
<cause idref="E66"/>
<clue>This <clueType>alteration</clueType> <linkTheme>in</linkTheme> NFkappaB activation occurred <linkCause>in the presence of</linkCause> normal expression of TCRzeta-associated signaling elements.</clue>
</event>
<event id="E65">
<type class="Positive_regulation"/>
<theme idref="T102"/>
<clue>This alteration in NFkappaB <clueType>activation</clueType> occurred in the presence of normal expression of TCRzeta-associated signaling elements.</clue>
</event>
<event id="E66">
<type class="Gene_expression"/>
<theme idref="T103"/>
<clue>This alteration in NFkappaB activation occurred in the presence of normal <clueType>expression</clueType> <linkTheme>of</linkTheme> TCRzeta-associated signaling elements.</clue>
</event>
<sentence id="S21">The clinical significance of these findings remains unclear.</sentence>
</AbstractText>
</Abstract></Article></MedlineCitation></PubmedArticle></PubmedArticleSet></Annotation>
